KRAS and non-small cell lung carcinoma: Interestingly, the KRAS mutation activated the Kras/YY1/ZNF322A/SHH axis by triggering the expression of downstream genes, including YY1, ZNF322A, and SHH, which promoted angiogenesis in NSCLC in vitro and in vivo (16).